Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Jiao FengWeiqi DaiYuqing MaoLiwei WuJingjing LiKan ChenQiang YuRui KongSainan LiJie ZhangJie JiJianye WuWenhui MoXuanfu XuChuan-Yong GuoPublished in: Journal of experimental & clinical cancer research : CR (2020)
Simvastatin can inhibit the HIF-1α/PPAR-γ/PKM2 axis, by suppressing PKM2-mediated glycolysis, resulting in decreased proliferation and increased apoptosis in HCC cells, and re-sensitizing HCC cells to Sora.